Production (Stage)
Entrada Therapeutics, Inc.
TRDA
$7.59
-$0.26-3.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.56M | 37.40M | 19.57M | 94.69M | 59.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.56M | 37.40M | 19.57M | 94.69M | 59.12M |
| Cost of Revenue | 32.07M | 33.41M | 31.26M | 32.04M | 28.61M |
| Gross Profit | -11.52M | 3.99M | -11.69M | 62.66M | 30.51M |
| SG&A Expenses | 10.27M | 9.86M | 9.97M | 9.24M | 9.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.35M | 43.27M | 41.23M | 41.27M | 38.01M |
| Operating Income | -21.79M | -5.87M | -21.66M | 53.42M | 21.11M |
| Income Before Tax | -17.35M | -739.00K | -15.89M | 57.79M | 25.33M |
| Income Tax Expenses | -- | -1.87M | -1.86M | 2.76M | 1.83M |
| Earnings from Continuing Operations | -17.35M | 1.13M | -14.03M | 55.03M | 23.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.35M | 1.13M | -14.03M | 55.03M | 23.50M |
| EBIT | -21.79M | -5.87M | -21.66M | 53.42M | 21.11M |
| EBITDA | -20.84M | -4.88M | -20.72M | 54.33M | 22.05M |
| EPS Basic | -0.42 | 0.03 | -0.35 | 1.61 | 0.70 |
| Normalized Basic EPS | -0.26 | -0.01 | -0.24 | 1.06 | 0.47 |
| EPS Diluted | -0.42 | 0.02 | -0.35 | 1.55 | 0.68 |
| Normalized Diluted EPS | -0.26 | -0.01 | -0.24 | 1.02 | 0.46 |
| Average Basic Shares Outstanding | 41.07M | 40.84M | 40.63M | 34.18M | 33.50M |
| Average Diluted Shares Outstanding | 41.07M | 43.05M | 40.63M | 35.51M | 34.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |